Sign In
Buy KMDA
$7.39
-0.120 (-1.60%)
At Close: Jun 03, 2026
Kamada's (KMDA) CEO Amir London on Q1 2021 Results - Earnings Call Transcript
12:41pm, Wednesday, 12'th May 2021
Kamada's (KMDA) CEO Amir London on Q1 2021 Results - Earnings Call Transcript
Kamada (KMDA) Q1 Earnings Top Estimates
11:16am, Wednesday, 12'th May 2021
Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities
07:00am, Wednesday, 12'th May 2021
REHOVOT, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months ended Ma
Kamada's Earnings Outlook
10:18am, Tuesday, 11'th May 2021
On Wednesday, May 12, Kamada (NASDAQ:KMDA) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
5 Health Care Stocks Trading with Low Price-Earnings Ratios
11:37am, Wednesday, 21'st Apr 2021
As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, othe
Checking Back In On Kamada
10:48am, Thursday, 01'st Apr 2021
It has been several years since we last did an in-depth piece on Israeli-based biotech concern Kamada. Early Wednesday, the company disclosed trial results on a candidate being evaluated as a potentia
Kamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 Trial
07:40am, Wednesday, 31'st Mar 2021
Kamada Ltd (NASDAQ: KMDA) has announced top-line results from its Phase 1/2 trial in Israel evaluating plasma-derived hyperimmune globulin (IgG) treatment for COVID-19. Kamada had announced the in
REHOVOT, Israel, March 31, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 1/2 open-label, singl
Kamada to Present at the Jefferies Global Plasma Summit
07:00am, Tuesday, 09'th Mar 2021
REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will pre
Transaction Furthers Kamada's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company
Kamada Files Annual Report for the Year Ended December 31, 2020
07:00am, Wednesday, 24'th Feb 2021
REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for t
Kamada's (KMDA) CEO Amir London on Q4 2020 Results - Earnings Call Transcript
10:36pm, Wednesday, 10'th Feb 2021
Kamada's (KMDA) CEO Amir London on Q4 2020 Results - Earnings Call Transcript
Kamada (KMDA) Misses Q4 Earnings and Revenue Estimates
09:25am, Wednesday, 10'th Feb 2021
Kamada (KMDA) delivered earnings and revenue surprises of -42.86% and -4.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Kamada Q4 Earnings
07:18am, Wednesday, 10'th Feb 2021
Shares of Kamada (NASDAQ:KMDA) decreased 1.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 69.23% over the past year to $0.04, which miss
Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities
07:00am, Wednesday, 10'th Feb 2021
REHOVOT, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and 12 months
